ISENTRESS
Total Payments
$6.5M
Transactions
25,741
Doctors
4,231
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $719,885 | 263 | 180 |
| 2023 | $524,561 | 501 | 371 |
| 2022 | $411,541 | 396 | 270 |
| 2021 | $664,579 | 281 | 213 |
| 2020 | $349,864 | 2,723 | 1,122 |
| 2019 | $1.1M | 6,991 | 1,917 |
| 2018 | $989,192 | 7,379 | 2,100 |
| 2017 | $1.8M | 7,207 | 2,105 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.4M | 250 | 66.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.4M | 725 | 20.8% |
| Food and Beverage | $442,132 | 23,544 | 6.8% |
| Travel and Lodging | $264,142 | 1,081 | 4.0% |
| Space rental or facility fees (teaching hospital only) | $59,800 | 46 | 0.9% |
| Consulting Fee | $44,213 | 50 | 0.7% |
| Education | $2,245 | 45 | 0.0% |
Payments by Type
Research
$4.4M
250 transactions
General
$2.2M
25,491 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Raltegravir Wash-Out Pharmacokinetics and Safety in Neonates IMPAACT P1097 | Merck Sharp & Dohme Corporation | $351,363 | 0 |
| STUDY NAME#Evaluation of pregnant and breastfeeding womens preferences and attitudes towards long-acting pre-exposure prophylaxis# A discrete choice experiment in South Africa and Botswana | Merck Sharp & Dohme LLC | $301,072 | 0 |
| Intensified antiretroviral therapy with raltegravir in acute HIV infection to limit establishment of the viral reservoir and preserve immune function | Merck Sharp & Dohme Corporation | $232,602 | 0 |
| Strategic Timing of Anti-Retroviral Treatment START | Merck Sharp & Dohme Corporation | $225,995 | 0 |
| VERY EARLY INTENSIVE TREATMENT OF HIV-INFECTED INFANTS TO ACHIEVE HIV REMISSION A PHASE I,II PROOF OF CONCEPT STUDY A Multi-Center Trial of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group IMPAACT | Merck Sharp & Dohme Corporation | $225,180 | 0 |
| A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir In HIV-1-Exposed Neonates at High Risk of Acquiring HIV-1 Infection | Merck Sharp & Dohme Corporation | $205,606 | 0 |
| STUDY NAME#Association of antiretroviral therapy and the menopausal transition with body composition change in women living with HIV | Merck Sharp & Dohme LLC | $149,618 | 0 |
| Hepatitis C treatment and cardiovascular risk modification in HIV-infected persons A prospective, observational study of endothelial function in HIV,HCV co-infected persons compared with HIV monoinfected controls with HIV virologic suppression | Merck Sharp & Dohme Corporation | $132,479 | 0 |
| VERY EARLY INTENSIVE TREATMENT OF HIV-INFECTED INFANTS TO ACHIEVE HIV REMISSION# A PHASE I,II PROOF OF CONCEPT STUDY A Multi-Center Trial of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group IMPAACT | Merck Sharp & Dohme LLC | $131,340 | 0 |
| Evaluation of pregnant and breastfeeding women's preferences and attitudes towards long-acting pre-exposure prophylaxis A discrete choice experiment in South Africa and Botswana | Merck Sharp & Dohme LLC | $129,031 | 0 |
| Effect of initiation of integrase inhibitors on medium term cardiovascular risk in HIV-infected patients. | Merck Sharp & Dohme Corporation | $123,628 | 0 |
| VERY EARLY INTENSIVE TREATMENT OF HIV-INFECTED INFANTS TO ACHIEVE HIV REMISSION# A PHASE I,II PROOF OF CONCEPT STUDY A Multi-Center Trial of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group IMPAACT | Merck Sharp & Dohme Corporation | $121,875 | 0 |
| Development of integrase resistance mutations using the GeneSeq integrase assay among participants in OPTIONS who experienced virologic failure | Merck Sharp & Dohme Corporation | $121,150 | 0 |
| VERY EARLY INTENSIVE TREATMENT OF HIV-INFECTED INFANTS TO ACHIEVE HIV REMISSION A PHASE I,II PROOF OF CONCEPT STUDY A Multi-Center Trial of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group IMPAACT | Merck Sharp & Dohme LLC | $114,305 | 0 |
| STUDY NAME#IMPAACT P1115, Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission# A Phase I,II Proof of Concept Study Version 2.0 DAIDS | Merck Sharp & Dohme LLC | $112,320 | 0 |
| Intensified antiretroviral therapy with raltegravir in acute HIV infection to limit establishment of the viral reservoir and preserve immune function | Merck Sharp & Dohme LLC | $111,920 | 0 |
| STUDY NAME#Identifying multi-modal signatures for health outcomes in PASC | Merck Sharp & Dohme LLC | $105,959 | 0 |
| A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Raltegravir MK-0518 1200 mg Once Daily Versus Raltegravir MK-0518 400 mg Twice Daily, Each in Combination With TRUVADA , in Treatment-Na ve HIV-1 Infected Subjects | Merck Sharp & Dohme Corporation | $96,662 | 0 |
| Advanced neuroimaging evaluation of the central nervous system biological changes associated with efavirenz therapy | Merck Sharp & Dohme Corporation | $88,740 | 0 |
| STUDY NAMEA Qualitative Study to Determine Biomedical HIV Prevention Preferences, Challenges and Facilitators of Uptake among Diverse At-Risk Women Living in the United States | Merck Sharp & Dohme Corporation | $88,023 | 0 |
Top Doctors Receiving Payments for ISENTRESS
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New Orleans, LA | $4.4M | 303 |
| , MD | Specialist | Los Angeles, CA | $97,973 | 166 |
| , D.O | Geriatric Medicine | Phoenix, AZ | $91,141 | 219 |
| , MD | Infectious Disease | Beverly Hills, CA | $67,515 | 94 |
| , M.D., PHD | Infectious Disease | San Francisco, CA | $63,806 | 75 |
| , D.O | Internal Medicine | Lansing, MI | $62,878 | 90 |
| , M.D | Internal Medicine | Las Piedras, PR | $58,907 | 93 |
| , M.D | Internal Medicine | Bronx, NY | $47,179 | 77 |
| , M.D | Infectious Disease | Denver, CO | $42,677 | 71 |
| , M.D | Internal Medicine | Seattle, WA | $42,015 | 77 |
| , MD | Infectious Disease | Newark, NJ | $41,220 | 58 |
| , D.O | Infectious Disease | Denver, CO | $39,107 | 51 |
| , MD | Internal Medicine | Fort Lauderdale, FL | $37,695 | 65 |
| , M.D | Infectious Disease | Miami Beach, FL | $37,424 | 57 |
| , M.D | General Practice | San Lorenzo, PR | $35,786 | 50 |
| , M.D | Infectious Disease | Sacramento, CA | $33,867 | 40 |
| , M.D | Psychiatry | Cambridge, MD | $30,394 | 107 |
| , MD | Internal Medicine | San Francisco, CA | $29,568 | 61 |
| , M.D | Infectious Disease | Fort Worth, TX | $29,386 | 46 |
| , MD | Infectious Disease | Chicago, IL | $29,263 | 42 |
| , MD | Infectious Disease | Briarcliff Manor, NY | $28,969 | 43 |
| , M.D | General Practice | Mayaguez, PR | $27,897 | 43 |
| , M.D | Infectious Disease | Sacramento, CA | $27,480 | 31 |
| , M.D | Family Medicine | Reading, PA | $27,059 | 59 |
| , M.D | Infectious Disease | Weymouth, MA | $26,133 | 30 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $6.5M
- Total Doctors 4,231
- Transactions 25,741
About ISENTRESS
ISENTRESS is a drug associated with $6.5M in payments to 4,231 healthcare providers, recorded across 25,741 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2024. In 2024, $719,885 was paid across 263 transactions to 180 doctors.
The most common payment nature for ISENTRESS is "Unspecified" ($4.4M, 66.8% of total).
ISENTRESS is associated with 20 research studies, including "Raltegravir Wash-Out Pharmacokinetics and Safety in Neonates IMPAACT P1097" ($351,363).